Inhibition of the extracellular enzyme ADAMTS4 prevents cardiac fibrosis and dysfunction.
Maria VistnesPugazendhi Murugan ErusappanAthiramol SasiEinar Sjaastad NordénKaja BergoAndreas RomaineIda Gjervold LundeLili ZhangMaria Belland OlsenJonas ØgaardCathrine Rein CarlsonChristian Hjorth WangJon RiiseChristen P DahlArnt Eltvedt FianeIdaMarie Hauge-IversenEmil EspeArne Olav MellebyTheis TønnessenJan Magnus AronsenIvar SjaastadGeir ChristensenPublished in: Cardiovascular research (2023)
Inhibition of ADAMTS4 improves cardiac function and reduces collagen accumulation in rats with cardiac pressure overload, possibly through a not previously known cleavage of molecules that control TGF-β availability. Targeting ADAMTS4 may serve as a novel strategy in heart failure treatment, in particular in heart failure with fibrosis and diastolic dysfunction.